Darifenacin, Solifenacin Urinary Incontinence Drugs Could Hit Market In 2003
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The urinary incontinence market could see the entry of two significant competitors in 2003, with recent NDA submissions for Pfizer’s darifenacin and Yamanouchi’s solifenacin (YM-905).